Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

Purpose: This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tolerability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients with advanced refractory solid tumors. Methods: Patients received LY2510924 at 20, 30, o...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Hara, Mark H., Messersmith, Wells, Kindler, Hedy, Zhang, Wei, Pitou, Celine, Szpurka, Anna M., Wang, Dan, Peng, Sheng-Bin, Vangerow, Burkhard, Khan, Anis A., Koneru, Mythili, Wang-Gillam, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097682/
https://www.ncbi.nlm.nih.gov/pubmed/32219196
http://dx.doi.org/10.1089/pancan.2019.0018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097682/
https://www.ncbi.nlm.nih.gov/pubmed/32219196
http://dx.doi.org/10.1089/pancan.2019.0018

Ejemplares similares